IP Library Granted Patent US 9,956,252
Granted Patent B2
US 9,956,252 · App. 14/848,143 · Granted May 1, 2018

Purified amniotic membrane compositions and methods of use

Inventors: Scheffer Tseng (Pinecrest, FL); Hua He (Miami, FL); Wei Li (Shenzhen, CN)
Assignee: TISSUETECH, INC.
A61K35/50A61K9/0014A61K9/0048A61K9/0053A61K9/06A61K9/08A61K31/738A61K35/48A61K38/1709A61K38/39A61K38/4886A61L15/44C07K14/4702C07K14/4718C07K14/78C07K14/8114A61L2300/412A61L2300/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,252
App. No.
14/848,143
Granted
May 1, 2018
Kind
B2
Abstract

Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.

Claims (20)

1. A composition comprising: (a) a water-soluble extract of amniotic membrane from frozen or previously frozen placenta, wherein the water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and high molecular weight hyaluronan (HA) that is cross-linked by a covalent bond to a heavy chain of inter-a-trypsin inhibitor (IαI); (b) a thickening agent; and (c) glycerin.

2. The composition of claim 1 , further comprising Smad7.

3. The composition of claim 1 , wherein the amniotic membrane is human, bovine, or porcine.

4. The composition of claim 1 , further comprising a pharmaceutically acceptable diluent, excipient, carrier, or combination thereof.

5. The composition of claim 1 , wherein the thickening agent is selected from the group consisting of: xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, sodium carboxymethyl cellulose, and combinations thereof.

6. The composition of claim 1 , wherein the composition is formulated as a non-solid dosage form.

7. The composition of claim 1 , wherein the composition is formulated as a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, or shampoo.

8. The composition of claim 1 , wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.

9. The composition of claim 1 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, ocular insertion, insertion between an eye and eyelid, or insertion in a conjunctival sac.

10. The composition of claim 1 , wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.

11. The composition of claim 1 , wherein the composition is formulated as a solid dosage form.

12. The composition of claim 4 , wherein the composition is formulated as a non-solid dosage form.

13. The composition of claim 4 , wherein the composition is formulated as a solution, drops, suspension, aerosol, paste, spray, ointment, oil, emulsion, cream, lotion, gel, a coated bandage, a patch, sticks, balms, or shampoo.

14. The composition of claim 4 , wherein the composition is formulated for ophthalmic administration, systemic administration, or topical administration.

15. The composition of claim 4 , wherein the composition is formulated for intraocular injection, subretinal injection, intravitreal injection, periocular injection, subconjuctival injection, retrobulbar injection, intracameral injection, sub-Tenon's injection, implantation, ocular implantation, ocular insertion, insertion between an eye and eyelid, or insertion in a conjunctival sac.

16. The composition of claim 4 , wherein the composition further comprises a penetration enhancer and an aqueous adjuvant.

17. The composition of claim 4 , wherein the composition is formulated as a solid dosage form.

18. The composition of claim 4 , wherein the composition is formulated as a solid oral dosage form.

19. The composition of claim 4 , wherein the composition is formulated for controlled release.

20. A wound dressing comprising the composition of claim 1 and a backing material.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FINANCIAL TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0165 →
SECURITY INTEREST Recorded Jun 7, 2024
From: BIOTISSUE HOLDINGS INC.; BIOTISSUE OCULAR INC.; BIOTISSUE SURGICAL INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 067666/0235 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2024
From: MIDCAP FUNDING IV TRUST
To: BIOTISSUE HOLDINGS INC. (F/K/A TISSUE TECH, INC.); BIOTISSUE OCULAR INC. (F/K/A BIO-TISSUE, INC.); BIOTISSUE SURGICAL INC. (F/K/A AMNIOX MEDICAL, INC.)
Reel/Frame 067666/0200 →
CHANGE OF NAME Recorded May 10, 2023
From: TISSUETECH, INC.
To: BIOTISSUE HOLDINGS INC.
Reel/Frame 063591/0802 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - TERM LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 060116/0413 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - REVOLVING LOAN Recorded May 18, 2022
From: TISSUETECH, INC.; BIO-TISSUE, INC.; AMNIOX MEDICAL, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 060116/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: BIO-TISSUE, INC.
To: TISSUETECH, INC.
Reel/Frame 036962/0403 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2015
From: TSENG, SCHEFFER; HE, HUA; LI, WEI
To: BIO-TISSUE, INC.
Reel/Frame 036962/0380 →
Continuity (5)
Continuation 11528980 · Sep 27, 2006
Continuation 13438759 · Apr 3, 2012
Continuation 13802264 · Mar 13, 2013
Provisional Application 60720760 · Sep 27, 2005
Related Publication 20160129049A1 · May 12, 2016